Replagal Evrópusambandið - íslenska - EMA (European Medicines Agency)

replagal

takeda pharmaceuticals international ag ireland branch - agalsídasi alfa - fabry sjúkdómur - Önnur meltingarvegi og efnaskipti vörur, - replagal er ætlað til langtíma ensím-skipti meðferð í sjúklinga með staðfest greining fabry sjúkdómur (a-galactosidase-skort).

Lamictal Tuggu-/dreifitafla 50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 50 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg

Lamictal Tuggu-/dreifitafla 5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 5 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg

Lamictal Tuggu-/dreifitafla 25 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 25 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg

Lamictal Tuggu-/dreifitafla 200 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 200 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg

Lamictal Tuggu-/dreifitafla 2 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 2 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 2 mg

Lamictal Tuggu-/dreifitafla 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

lamictal tuggu-/dreifitafla 100 mg

glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 100 mg